Literature DB >> 28535005

RPN11 deubiquitinase promotes proliferation and migration of breast cancer cells.

Guoqing Luo1, Ningdong Hu2, Xu Xia2, Jingjing Zhou2, Changsheng Ye1.   

Abstract

The deubiquitinase enzyme RPN11 is involved in oncogenesis in various types of cancer. However, in breast cancer, the expression levels, prognostic relevance and biological function of RPN11 remains unclear. In the present study, RPN11 expression levels in breast cancer tissues and adjacent non‑tumor tissues were determined by reverse transcription‑quantitative polymerase chain reaction and immunohistochemical staining, and the association of RPN11 with clinicopathological features of breast cancer was evaluated. RPN11 expression was upregulated in breast cancer tissues compared with healthy tissues. Additionally, high expression levels of RPN11 may be an indicator of poor prognosis, as validated by a breast cancer cohort from the Gene Expression Omnibus database. Knockdown of RPN11 in MDA‑MB‑231 and T47D cells significantly reduced cell proliferation and enhanced G0/G1 arrest and apoptosis. Exogenous overexpression of RPN11 in MCF7 and Hs578T cells promoted cell growth and inhibited apoptosis. In addition, knockdown of RPN11 abrogated cell migration and reduced epithelial‑mesenchymal transition. In conclusion, these findings suggested that RPN11 may function as an oncogene and its upregulation in breast cancer suggests that it may be a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28535005     DOI: 10.3892/mmr.2017.6587

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  17 in total

1.  Hes-related family BHLH transcription factor with YRPW motif 1-activated proteasome 26S subunit, non-ATPase 14 regulates trophoblast function and endometrial angiogenesis.

Authors:  Lingyun Zhang; Shan Zhang; Fangrong Chen
Journal:  Exp Ther Med       Date:  2022-05-31       Impact factor: 2.751

2.  POH1 Knockdown Induces Cancer Cell Apoptosis via p53 and Bim.

Authors:  Chun-Hua Wang; Shi-Xun Lu; Li-Li Liu; Yong Li; Xia Yang; Yang-Fan He; Shi-Lu Chen; Shao-Hang Cai; Hong Wang; Jing-Ping Yun
Journal:  Neoplasia       Date:  2018-03-21       Impact factor: 5.715

3.  Unstructured Biology of Proteins from Ubiquitin-Proteasome System: Roles in Cancer and Neurodegenerative Diseases.

Authors:  Kundlik Gadhave; Prateek Kumar; Shivani K Kapuganti; Vladimir N Uversky; Rajanish Giri
Journal:  Biomolecules       Date:  2020-05-21

Review 4.  Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.

Authors:  Jinyoung Park; Jinhong Cho; Eun Joo Song
Journal:  Arch Pharm Res       Date:  2020-11-09       Impact factor: 4.946

Review 5.  Molecular Mechanisms of DUBs Regulation in Signaling and Disease.

Authors:  Ying Li; David Reverter
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

6.  PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca2+ Imbalance.

Authors:  Hong-Jae Lee; Dong-Min Lee; Min-Ji Seo; Ho-Chul Kang; Seok-Kyu Kwon; Kyeong-Sook Choi
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 6.208

7.  The prognostic value of USP14 and PSMD14 expression in non-small cell lung cancer.

Authors:  Jian Lei; Xiaoliu Liu; Wei Liu; Yun Zhang; Zhihong Liu
Journal:  Ann Transl Med       Date:  2021-06

8.  Upregulation of deubiquitinase PSMD14 in lung adenocarcinoma (LUAD) and its prognostic significance.

Authors:  Ling Zhang; Hui Xu; Chunping Ma; Jieru Zhang; Yuanjie Zhao; Xiaomei Yang; Shusheng Wang; Dawei Li
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

9.  Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma.

Authors:  Si Zhang; Siwei Yu; Jiulong Wang; Zhigang Cheng
Journal:  Biosci Rep       Date:  2021-03-26       Impact factor: 3.840

10.  Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.

Authors:  Tianshui Sun; Zhuonan Liu; Fangfang Bi; Qing Yang
Journal:  Mol Oncol       Date:  2021-08-25       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.